



**Acta Botanica  
Mexicana**

# Ethnopharmacological studies of *Cecropia obtusifolia* (Urticaceae) and its importance in the treatment of type 2 diabetes mellitus: A mini-review

## Estudios etnofarmacológicos de *Cecropia obtusifolia* (Urticaceae) y su importancia en el tratamiento de la diabetes mellitus tipo 2 (DM-2): una mini-revisión

Jorge David Cadena-Zamudio<sup>1</sup> , María del Pilar Nicasio-Torres<sup>2</sup> , José Antonio Guerrero-Analco<sup>1</sup> , Enrique Ibarra-Laclette<sup>1,3</sup>

### Abstract:

**Background and Aims:** Diabetes mellitus type 2 (DM-2) is one of the most recurrent chronic diseases worldwide, it is usually treated with synthetic medications, many of which have important repercussions on the patient's body. For this reason, ethnopharmacology has become more important in recent years, because a large number of plant resources origin are used in medicine and are shown as positive effect in the treatment of different diseases, including DM-2. Therefore, the aim of this review is to highlight how previous studies are adding to the understanding and knowledge of the biological effects reported in *Cecropia obtusifolia*, a tropical plant included in the Herbal Pharmacopoeia of the United Mexican States (FHEUM), which is commonly used to treat DM-2.

**Methods:** A profound literature review was carried out on *C. obtusifolia*, focusing on diverse phytochemical, pharmacological, clinical and toxicological studies, as well as on some other relevant research findings.

**Key results:** It is recognized that this species is able to decrease serum glucose, cholesterol and triglyceride levels due to its hypoglycemic and hypolipidemic properties, which has been demonstrated both in animal and human experimental models, attributing these effects to chlorogenic acid and isoorientin. These previous reports suggest that *C. obtusifolia* is a promising candidate for the development of a phytopharmaceutical which could be used in the treatment of DM-2.

**Conclusions:** We provide an updated and complete overview of the phytochemistry, traditional uses, and pharmacological activities of *C. obtusifolia*. Regarding its pharmacological activities, we focus mainly on the hypoglycemic effect of this plant which supports its traditional use in DM-2 control. Moreover, the present knowledge was critically assessed to provide some evidence and justifications and propose future research prospects.

**Key words:** chlorogenic acid, hypoglycemic effect, ethnopharmacology, medicinal plants.

### Resumen:

**Antecedentes y Objetivos:** La diabetes mellitus tipo 2 (DM-2) es una de las enfermedades crónicas recurrentes más comunes, generalmente se trata con medicamentos sintéticos, muchos de los cuales tienen importantes repercusiones en el cuerpo del paciente. Por esta razón, la etnofarmacología se ha vuelto más importante en los últimos años, porque una gran cantidad de recursos de origen vegetal son utilizados en medicina y muestran un efecto positivo en el tratamiento de diferentes enfermedades, incluyendo DM-2. Por lo tanto, el objetivo de esta revisión es destacar cómo los estudios previos se suman a la comprensión y el conocimiento de los efectos biológicos informados en *Cecropia obtusifolia*, una planta tropical incluida en la Farmacopea Herbolaria de los Estados Unidos Mexicanos (FHEUM), comúnmente usada para tratar DM-2.

**Métodos:** Se realizó una revisión profunda de la literatura sobre *C. obtusifolia*, centrándose en diversos estudios fitoquímicos, farmacológicos, clínicos y toxicológicos, así como en otros hallazgos relevantes de investigación.

**Resultados clave:** Se reconoce que esta especie es capaz de disminuir los niveles séricos de glucosa, colesterol y triglicéridos, debido a sus propiedades hipoglucémicas e hipolipidémicas reductoras de lípidos, que se han demostrado tanto en modelos experimentales animales como en humanos, atribuyendo estos efectos al ácido clorogénico y la isoorientina. Estos informes previos sugieren que *C. obtusifolia* es un candidato prometedor para el desarrollo de un fitofarmacéutico que podría usarse en el tratamiento de DM-2.

**Conclusiones:** Brindamos una visión general actualizada y completa de la fitoquímica, los usos tradicionales y las actividades farmacológicas de *C. obtusifolia*. En cuanto a sus actividades farmacológicas, nos centramos principalmente en el efecto hipoglucémico de esta planta que apoya su uso tradicional en el control de DM-2. Además, el conocimiento actual se evaluó críticamente para proporcionar algunas pruebas y justificaciones y proponer futuras perspectivas de investigación.

**Palabras clave:** ácido clorogénico, efecto hipoglucémico, etnofarmacología, plantas medicinales.

1 Instituto de Ecología, A.C. (INECOL), Red de Estudios Moleculares Avanzados (REMAV), 91070 Xalapa, Veracruz, México.

2 Instituto Mexicano del Seguro Social (IMSS), Centro de Investigación Biomédica del Sur (CIBIS), 62790 Xochitepec, Morelos, México.

3 Author for correspondence: enrique.ibarra@inecol.mx

Received: March 21, 2018.

Revised: Mayo 2, 2018.

Accepted by Marie-Stéphanie Samain: June 27, 2018.

Published Online first: October 10, 2018.

Published: Acta Botanica Mexicana 126 (2019).

To cite as:

Cadena-Zamudio, J. D., M. P. Nicasio-Torres, J. A. Guerrero-Analco and E. Ibarra-Laclette. 2018(2019). Ethnopharmacological studies of *Cecropia obtusifolia* (Urticaceae) and its importance in the treatment of type 2 diabetes mellitus: A mini-review. Acta Botanica Mexicana 126: e1361. DOI: 10.21829/abm126.2019.1361



This is an open access article under the Creative Commons 4.0 Attribution-Non commercial License (CC BY-NC 4.0 International).

e-ISSN: 2448-7589

## Introduction

Many plant species naturally produce compounds that exert therapeutic action for humans, so they have been called “medicinal plants” since antiquity. It is estimated that around 35,000 species that are used for medicinal purposes have been classified worldwide (Ghulam et al., 2017), and the World Health Organization (WHO) calculates that approximately 80% of the population around the world uses medicinal plants for the treatment of diseases (Rivera-Mondragón et al., 2017).

The total floristic wealth of Mexico is constituted of 23,314 species, placing it in the fourth place in the world (Villaseñor, 2016). Of this total, it has been reported that around 3000 species of angiosperm plants (approximately 15% of the total flora) have medicinal properties, i.e., one in seven species possesses some curative features (Ocegueda et al., 2005; Villaseñor, 2016). For these reasons, scientific attention has now been diverted to ethnomedicine, since in the last years an increase in demand for natural products from medicinal herbs products has developed, since the modern pharmacopoeia includes about 25% of the medicines that have been derived from this type of plants (Ghulam et al., 2017). For example, in Germany, there are two commercial phytopharmaceuticals used for the treatment of diabetes from endemic plants of the American continent, which are widely used in traditional Mexican medicine. The first one is Hando, which is based on nopal (*Opuntia streptacantha* Lem.) and is manufactured by the company Hando Austria. The second phytomedicine is Sucontral, which is produced from the medicinal plant Copalchi (*Hintonia latiflora* (DC) Bullock), and is manufactured by the company Harras Pharma, Munich. (Andrade-Cetto and Heinrich, 2005).

Therefore, it is urgent and necessary to conduct studies of medicinal plants for the identification and characterization of the active compounds of complex mixtures that allow different analytical and biomedical tests to indicate their biological activity (treatment of degenerative diseases such as diabetes among others), efficacy, and toxicity to prevent side effects. Diverse natural products based on medicinal plants (herbal medicines) exist on the market, with very little information about their chemical composition and pharmacological effects that can have

adverse effects, different from those expected (positive effects on health).

Therefore, this work contains a compilation of different studies carried out in *Cecropia obtusifolia* Bertol., which is widely used for the treatment of diabetes mellitus type 2 (DM-2). This disease is characterized by the lack of sensitivity to insulin (resistance to insulin) and insufficient pancreatic secretion and inability to compensate for these alterations (dysfunction of  $\beta$  cells), resulting in hyperinsulinemia, hyperlipidemia, hypercholesterolemia, glucose intolerance and hypertension (Ross et al., 2004). Therefore, this plant has been widely used in traditional medicine in Mexico due to its hypoglycemic and hypolipidemic effects, which has led the scientific community to focus efforts to elucidate the modes of action of this species in DM-2.

## Materials and Methods


A traditional manual search approach was used in which, by using keywords, reliable, accurate and up-to-date material related to phytochemical, pharmacological, toxicological and clinical studies of the medicinal plants, *C. obtusifolia*, were identified. Searches of scientific reports, books, as well as postgraduate theses were done mainly using three bibliographic databases (PubMed, Scopus, Web of Science) and one full-text database (Google Scholar). Literature was categorized, read and analyzed to summarize and synthesize some key points, which are discussed to highlight their importance and based on this previous knowledge identify/suggest areas of opportunity for future research.

## Results

### Importance of medicinal plants in the ethnopharmacology

Natural products research is commonly related to the discovery and development of drugs based on ethnobotanical information, where the plants have formed the base of sophisticated systems of traditional medicine, based on empirical findings, and the knowledge associated to their uses has been transmitted for hundreds and thousands of years (Buenz et al., 2017) (Fig. 1).

Natural products contain bioactive phytochemicals that are becoming increasingly important in foods such as Nutraceuticals (NC) (Foster et al., 2005). Therefore, ethno-



**Figure 1:** Methodology traditionally used for the identification of medicinal plants through life experiences between generations. Design by J. D. Cadena-Zamudio. Based on the adaptation of [Buenz et al., 2017](#).

pharmacological research has focused on obtaining natural products and generating libraries with them, since they have shown a higher success rate compared to the libraries obtained by combinatorial chemistry. Each combinatorial approach has its own exclusive high-performance coding and selection strategy, which leads to different success and performance rates between each method ([Sukuru et al., 2009](#); [Liu et al., 2017](#)). Since the primary and secondary metabolites examined and obtained from plants have already presumed different biological functions, and although these libraries have fewer compounds than those obtained by combinatorial chemistry, the percentage of products with biological activity is higher in natural products, which has been corroborated thanks to the use of techniques such as high performance like high-throughput screening (HTS), where the timely detection of natural products has reported higher rates ([Sukuru et al., 2009](#); [Harvey et al., 2015](#); [Buenz et al., 2017](#)). This suggests that the historical ethnopharmacological uses of plant-based drugs can be used as a preliminary screening criterion for the identification of bioactive compounds, since natural products and their derivatives represent around 50% of the

total number of drugs in clinical use in the world, being the angiosperms 25% of the total; causing a quarter of all medical prescriptions to be formulations based on substances derived from plants or synthetic analogues derived from natural compounds ([Castillo-España et al., 2009](#)).

Unfortunately, the continuous loss of knowledge in traditional medicine and biodiversity, as a consequence of human population growth, has resulted in the loss of original resources (natural sources), which has motivated the scientific community to increase efforts to restore and document the ethnopharmacological use of natural products in the original communities. These tools are of great utility for future discovery of new biologically active compounds ([Martínez-Francés et al., 2015](#); [Buenz et al., 2017](#)).

### Species used for the treatment of DM-2

Mexico is considered one of the countries with the greatest biodiversity in the world; it is estimated that there are 23,400 vascular plants in this country, of which around 3000 have medicinal effects ([Villaseñor, 2016](#)). Of these plant species, 1200 have hypoglycemic activity and are used in traditional medicine for treatment with DM-2 ([An-](#)

drade-Cetto et al., 2010). The reports suggest that the hypoglycemic activity is conferred by some kind of secondary metabolite that is biosynthesized by these plants (Hernández-Galicia et al., 2007; Romero-Cerecero et al., 2009; Andrade-Cetto et al., 2010; Alonso-Castro et al., 2016). The chemical and pharmacological evaluations to confirm or discard the antidiabetic properties (and/or hypoglycemic effect) have been carried out in 5% of these reported species only, and the pharmacological mechanism of action has been studied in very few of them (Alarcón-Aguilar et al., 2002; Ocegueda et al., 2005).

In Mexico, seven species stand out for being widely used in traditional medicine to treat DM-2; phytochemical and pharmacological studies exist for all of them, proving their activity, both *in vivo* or *in vitro* (Pérez et al., 1984; Román-Ramos et al., 1991; Alarcón-Aguilar et al., 2002; Andrade-Cetto and Heinrich, 2005). Within this select group of plants, most of them are now included in the Herbal Pharmacopoeia of the United Mexican States (FEUM), such as the “nopal” (*Opuntia streptacantha*) and “tronadora” (*Tecoma stans* (L.) Juss. ex Kunth). Hypoglycemic activity of *O. streptacantha* was demonstrated in healthy rabbits with temporal hyperglycemia and in rabbits with moderate diabetes (Andrade-Cetto and Heinrich, 2005). On the other hand, Mellado and Lozoya (1985) showed the hypoglycemic effect of *T. stans* infusion through intravenous administration in dogs, and likewise, Aguilar-Santamaría et al. (2009) identified antidiabetic activities in streptozotocin (STZ) rats, including the inhibition of intestinal glucosidase and postprandial antihyperglycemic effects, as well as hypocholesterolemic and hypotriglyceridemic effects.

Other plants studied are commonly known in Mexico as “trompetilla” (*Bouvardia ternifolia* (Cav.) Schltdl.), “hierba dorada” (*Brickellia veronicifolia* (Kunth) A. Gray) and “cuajilote” (*Parmentiera aculeata* (Kunth) Seem.), their aqueous extracts showing hypoglycemic activity administered to normoglycemic and induced diabetic mice (Pérez-Gutiérrez et al., 1998). Similar studies have been conducted in *Ibervillea sonora* (S. Watson) Greene and *Parkinsonia aculeata* L., species commonly known as “wereke” and “retama”, respectively (Alarcón-Aguilar et al., 2002, 2005; Hernández-Galicia et al., 2007; Leite et

al., 2007). Finally, the Urticaceae family has considered its wide use of traditional medicine, of which the empirical treatment of DM-2 stands out, where the most used for this condition are *Cecropia peltata* L. and *Cecropia obtusifolia* (Giovannini et al., 2016).

### *Cecropia obtusifolia*, geographical distribution and traditional use

*Cecropia obtusifolia* (Fig. 2), a plant of the family Urticaceae, popularly known as “guarumbo”, “ghancarro”, “hormiguillo”, “chiflon” and “koochlé”, is used in Mexico by the traditional healers for DM-2 treatment (Martínez-Toledo et al., 2008). This species is originally from Central America and it is distributed from Mexico to northern South America; it grows in tropical, warm, semi-warm and temperate climates, from regions bordering the coasts and up to 1500 m above sea level. *Cecropia obtusifolia* grows in tropical forests and in secondary vegetation of deciduous, subperennial or evergreen forests that have been disturbed; sometimes it is associated with xerophilous scrub of cacti or cedar, in pasture and in mixed oak-pine forest (Argueta et al., 1994; Aguilar et al., 1998; Berg et al., 2005). In Mexico, it is distributed on the Mexican Gulf slope, from the states of Tamaulipas to Quintana Roo, and in the Pacific, from Sinaloa to Chiapas, Puebla, Hidalgo and Guanajuato (Argueta et al., 1994; Andrade-Cetto and Heinrich, 2005).

The use of *C. obtusifolia* to treat diabetes was reported in the states of Hidalgo, Guerrero, Veracruz, Yucatán, Campeche, Tabasco, México, Oaxaca and Chiapas (Andrade-Cetto and Heinrich, 2005). The dried leaves (~15 g) are boiled in water (~500 ml), and the resulting infusion should be cooled and then filtered, to drink it throughout the day as “agua de uso” (Andrade-Cetto and Heinrich, 2005). The inhabitants of the community of Tlanchinol in the state of Hidalgo also use the tree bark for the treatment of the same disease (Andrade-Cetto, 1999). Furthermore, infusion of *C. obtusifolia* is used for the treatment of nerve conditions, as fever reducer (antipyretic), cardiac conditions, liver and pulmonary diseases, asthma, flu, wounds, scorpion and ant bites, bone fractures, kidneys, rheumatoid arthritis and wart removal, among many others (CONABIO, 2017).





**Figure 2:** Guarumbo (*Cecropia obtusifolia* Bertol). Photo by J. D. Cadena-Zamudio, from a plant growing in the “Los Tuxtlas” Tropical Biology Station-UNAM, San Andrés Tuxtla, Veracruz, Mexico.

### Chemical compounds reported in *Cecropia obtusifolia*

Due to the properties mentioned above, some studies have been carried out to ascertain its chemical composition, the presence of sterols, tannins and monosaccharides, e.g., L-rhamnose, D-glucose and D-xylose was demonstrated; the presence of saponins and phenolics has also been reported, as well as the absence of alkaloids, flavonols and cardiotonic glycosides (Trejo, 1983). Recent studies reported the presence of 18 new compounds identified from *C.*

*obtusifolia* leaves (Table 1), which have been shown to have both antidiabetic and anti-inflammatory activities.

### Biological activity of the main phytochemicals identified in *Cecropia obtusifolia*

As mentioned above, different parts like leaves and tree bark of *C. obtusifolia* are used to treat various illnesses, mainly DM-2; the hypoglycemic effect was attributed to two secondary metabolites in particular, chlorogenic acid (CGA) and isoorientin (ISO) (Andrade-Cetto and Wieden-

**Table 1:** Compounds identified in *Cecropia obtusifolia* Bertol. and its potential biological activities. DCME: dichloromethane extract; NR: not reported or very low concentrations. Modified from [Rivera-Mondragón et al. \(2017\)](#).

Compound	Part of the plant	Concentration	Biological activity	References
4,22-Cholestadien-3-one	leaves	DCME	NR	<a href="#">Guerrero et al. (2010)</a>
4-Cholestene-3,24-dione	leaves	DCME	NR	<a href="#">Guerrero et al. (2010)</a>
β-Sitosterol	leaves	NR	Anti-inflammatory	<a href="#">Andrade-Cetto and Heinrich (2005)</a> ; <a href="#">Loizou et al. (2010)</a>
Stigmast-4-en-3-one	leaves	DCME	Anti-inflammatory, Anti-diabetic	<a href="#">Jamaluddin et al. (1995)</a> ; <a href="#">Alexander-Lindo et al. (2004)</a> ; <a href="#">Guerrero et al. (2010)</a> ; <a href="#">Tewtrakul et al. (2010)</a>
Stigmasterol	leaves	NR	Anti-inflammatory	<a href="#">Andrade-Cetto and Heinrich (2005)</a> ; <a href="#">Gabay et al. (2010)</a>
Aloe-emodin	leaves	NR	Anti-inflammatory	<a href="#">Choi et al. (2013)</a> ; <a href="#">Yan et al. (2013)</a> ; <a href="#">Kshirsagar et al. (2014)</a> ; <a href="#">Park et al. (2016)</a>
Chrysophanol	leaves	NR	Anti-inflammatory	<a href="#">Choi et al. (2013)</a> ; <a href="#">Yan et al. (2013)</a> ; <a href="#">Kshirsagar et al. (2014)</a> ; <a href="#">Park et al. (2016)</a>
Emodin	leaves	NR	Anti-inflammatory	<a href="#">Choi et al. (2013)</a> ; <a href="#">Yan et al. (2013)</a> ; <a href="#">Kshirsagar et al. (2014)</a> ; <a href="#">Park et al. (2016)</a>
Physcion	leaves	NR	Anti-inflammatory	<a href="#">Choi et al. (2013)</a> ; <a href="#">Yan et al. (2013)</a> ; <a href="#">Kshirsagar et al. (2014)</a> ; <a href="#">Park et al. (2016)</a>
Rehin	leaves	NR	Anti-inflammatory	<a href="#">Choi et al. (2013)</a> ; <a href="#">Yan et al. (2013)</a> ; <a href="#">Kshirsagar et al. (2014)</a> ; <a href="#">Park et al. (2016)</a>
1-(2-Methyl-1-nonen-8-yl)- aziridine	leaves	NR	NR	<a href="#">Andrade-Cetto and Heinrich (2005)</a>
2-Methylbenzaldehyde	leaves	DCME	NR	<a href="#">Guerrero et al. (2010)</a>
2,3-Dihydrobenzofuran	leaves	DCME	NR	<a href="#">Guerrero et al. (2010)</a>
3'-Methoxyacetophenone	leaves	DCME	NR	<a href="#">Guerrero et al. (2010)</a>
4-Ethyl-5-(n-3valeroil)-6- hexahydrocoumarin	leaves	NR	NR	<a href="#">Andrade-Cetto and Heinrich (2005)</a>
4-Vinyl-2-methoxy-phenol	leaves	DCME	NR	<a href="#">Guerrero et al. (2010)</a>
Palmitic acid	leaves	DCME	Anti-inflammatory	<a href="#">Guerrero et al. (2010)</a>
Stearic acid	leaves	DCME	Anti-inflammatory	<a href="#">Guerrero et al. (2010)</a> ; <a href="#">Pan et al. (2010)</a>

[feld, 2001](#)), due to the stimulation in the glucose uptake 2-NBD and the inhibition of glucose-6-phosphatase, resulting in an inhibition of the production of hepatic glucose and increase in the tolerance to glucose ([Hemmerle et al., 1997](#); [Andrade-Cetto and Wiedenfeld, 2001](#)).

### Pharmacological studies

[Pérez et al. \(1984\)](#) tested the hypoglycemic effect of *C. obtusifolia* in mice with induced diabetic with Alloxan (toxic compound that acts on the islets of Langerhans, used in experiments to induce diabetes mellitus in animal models). The same hypoglycemic effect was subsequently observed in hyperglycemic rabbits ([Román-Ramos et al., 1991](#)). In 1997, Hemmerle et al. tested the effect of CGA and its deriv-

atives in the microsomal activity of glucose 6-phosphatase, demonstrating inhibition of glycogenolysis, gluconeogenesis, and reduction of liver glucose production. [Andrade-Cetto and Wiedenfeld \(2001\)](#) carried out studies on diabetic rats induced with STZ and treated with *C. obtusifolia* aqueous and butanolic extracts at doses of 90 mg/kg and 150 mg/kg for the first one, and 9 mg/kg and 15 mg/kg for the second one, finding a significant decrease in plasma glucose levels three hours after treatment. [Sezik et al. \(2005\)](#) showed that ISO, administered by oral route for two weeks in diabetic rats induced with STZ, decreased their glucose, cholesterol and triglycerides levels from the fifth day of treatment, keeping it up to 12 days after the suspension of the administration of the compound. [Nicasio-Torres et al. \(2005\)](#) reported con-



centrations of  $19.84 \pm 1.64$  mg of CGA/g in the dry leaves of *C. peltata* and *C. obtusifolia*; the extract of the last one showed a decrease in plasma glucose levels (45.6%) between two and four hours after the oral administration. This proved that the hypoglycemic effect is correlated with the CGA concentrations in plant leaves. Andrade-Cetto et al. (2008) showed that the butanolic extract of *C. obtusifolia* leaves decreases the postprandial hyperglycemia in rats pre-treated with STZ; this effect was associated with the intestinal  $\alpha$ -glucosidase enzyme inhibition, thus preventing the splitting of complex carbohydrates and delaying the absorption of glucose. Similarly, Alonso-Castro et al. (2008), reported that the CGA is able to stimulate the production of glucose in sensitive and insulin resistant adipocytes. In 2010, Andrade-Cetto and Cárdenas Vázquez found that the mechanism of the hypoglycemia effect of *C. obtusifolia* is due to the inhibition of the enzyme glucose 6-phosphatase in the gluconeogenesis, which results in a reduction in the production of hepatic glucose. Sezik et al., in 2005, reported the hypoglycemia and hypolipidemic effects of ISO in STZ-induced diabetic rats, dosing orally for two weeks, demonstrating that ISO can reduce the levels of glucose, cholesterol, and triglycerides from the fifth day of treatment and hold it up to ten days after the suspension of the treatment.

### Toxicological studies

In the toxicological studies, Pérez-Guerrero et al. (2001) quantified the lethal dose ( $LD_{50}$ ) in rats, using the aqueous extract of *C. obtusifolia* leaves and continued to administer intraperitoneally, obtaining a dose of  $1.45 \pm 0.07$  g/kg (equivalent to  $11.21 \pm 0.52$  g/kg of dry leaf per body weight). Another study of this type, but with a genotoxic approach, was carried out by Martínez-Toledo et al. (2008), evaluating the possible effects of the aqueous extract of *C. obtusifolia* in somatic mutation tests in *Drosophila melanogaster* Meigen wings and a micronucleus assay in lymphocytes obtained from patients treated with the extract; the results obtained did not show genotoxic or cytotoxic effects caused by the extract.

### Clinical studies

There are some interesting data about clinical studies that involved the antidiabetic effects of *C. obtusifolia*. For example, the study done by Herrera-Arellano et al. (2004) car-

ried out a double-blind design with uncontrolled diabetic patients between 30 and 60 years. Patients were provided with tea bags from *C. obtusifolia* leaves to prepare the infusions with an oral dose of  $2.99 \pm 0.14$  mg/g of CGA before each meal. The length of the treatment was 21 days and showed that glucose (15.25%), cholesterol (14.62%) and triglycerides blood levels (42%) decreased with respect to the control group. A similar study was carried out by Revilla-Monsalve et al. (2007), in which they took diabetic patients without pre-treatment with conventional oral hypoglycemic drugs, and they were treated with infusions of *C. obtusifolia* leaves using concentrations of CGA=2.91 mg and ISO=2.4 mg; the patients displayed a significant reduction in glycosylated hemoglobin (HbA1c) after six weeks, without finding significant changes in the patient's insulin secretion, nor in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALKP) levels; indicating no hepatotoxicity during the treatment.

### Other biological activities

In this respect, antihypertensive effects are identified; since Salas et al. (1987) reported a drop-in blood pressure (-23.5% with respect to pre-injection values) in rats with consistent hypertension, when they were administered the lyophilized aqueous extract from leaves. In the same way, analgesic and anti-inflammatory effects have been reported (Pérez-Guerrero et al., 2001). This justifies its use in different pathologies such as inflammatory, rheumatic and renal ones, which can also be associated with DM-2 symptoms and its complications.

## Discussion and Conclusions

In Mexico, there is an extensive variety of treatments based on medicinal plants (phytomedicines). All these plants are part of the traditional Mexican herbalism, comprehending around 3000 species. Due to this abundant species number, Mexico is positioned as one of the world's most important countries regarding the number of registered and used medicinal plants (Barragán, 2006). In both developed and developing countries, the use and commercialization of phytomedicines and natural products for medicinal purposes has grown in recent years. In addition, it is important to note that due to the immense diversity of possible

bioactive molecules present in plants, there is currently an increase of patent protected allopathic medicines which are from plant origin. Due to this, the production of secondary metabolites using plant cell cultures, the generation of knowledge about the biosynthetic pathways and the enzymes involved, their functions in the host and the influence of environmental conditions in their synthesis are only some of the niches of opportunities for investigative work.

In the particular case of *C. obtusifolia*, despite its relevance and potential at the pharmacological level, there are no genetic or genomic data for this species and, for example, it is unknown whether orthologous genes already reported in other plant species are also responsible for the synthesis of interesting metabolites such as chlorogenic acid and isoorientin. In addition, the questions are how different metabolic pathways modulate the synthesis of active molecules and how these affect the synthesis of these molecules remain unanswered (Wang et al., 2009). Most of the specialized metabolites of interest are produced in non-model plants for which genomic/transcriptomic sequence information is not yet available. Fortunately, NGS (Next Generation Sequences) technologies can be implemented to sequence plant transcriptomes from medicinal plants (Morozova et al., 2009; Fonseca et al., 2016). The massive gene lists that can be generated thus represent a seemingly unlimited catalog of enzymes, transporters, or regulators to be used in synthetic biology programs (Ozso-lak and Milos, 2011). This wealth of sequences has shifted the paradigm in gene discovery quests, which no longer focus on the isolation of candidate plant gene sequences, but rather on how to find the right one in the immensity of duplicated and neofunctionalized genes, which through evolution have resulted in hundreds of thousands of different specialized metabolites that can be found in the plant kingdom (Saito and Matsuda, 2010). If sequence assembly is complemented with extensive *in silico* analysis, a (tentative) functional annotation can be assigned and then this information can be used to reconstruct metabolic pathways and discover missing enzymes in the pathways (Metzker, 2010; Garber et al., 2011; Fonseca et al., 2016).

Besides gene sequences, metabolic pathways construction will heavily depend on metabolomics for validation (Saito and Matsuda, 2010). Plants are challenging in

this regard as a single plant (cell) can harbor thousands of metabolites, many of whose structure is yet unknown. Plant metabolomics will require both targeted and non targeted analysis, within which high resolution mass spectrometry based techniques, along with nuclear magnetic resonance spectroscopy, will be most suitable because of the remaining need for the annotation of unknown compounds (Saito and Matsuda, 2010; Soda et al., 2015; Mochida and Shinozaki, 2017). Here, we propose *C. obtusifolia* as a “non-model” plant species which should be used for, by the systematic integration of transcriptomics and metabolomics, investigating the molecular basis of the synthesis and function of some metabolites, mainly from those which have potential to treat important diseases.

## Author contributions

JCZ and EIL contributed to the writing of the work and critical review of its intellectual manuscript. PNT and JGA substantially contributed to the conception and revision. All authors contributed to the design and writing, revision, and approval of the final manuscript. Consent is given for its publication. All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript. The authors declare that they have no competing interests.

## Funding

This work was supported by the Consejo Nacional de Ciencia y Tecnología (CONACyT), (grant 223323) (EIL), to the working group of Pilar Nicasio-Torres in the biotechnology laboratory of CIBIS-IMSS, and to the working group of José Antonio Guerrero-Analco in the laboratory of natural products chemistry of Instituto de Ecología, A.C. (INECOL); as well as through financing of the postgraduate scholarship in Master of Science (608610) awarded to Jorge David Cadena Zamudio.

## Acknowledgments

Thanks to Consejo Nacional de Ciencia y Tecnología (CONACyT); special thanks go to Juan Luis Monribot Villanueva, Alexandro Alonso-Sánchez and Emanuel Villafán de La Torre for their many valuable discussions and their wholehearted help and supports.



## Literature cited

- Aguilar, A., J. R. Camacho, S. Chino, P. Jácquez and M. E. López. 1998. Plantas medicinales del herbario del IMSS: su distribución por enfermedades. Instituto Mexicano del Seguro Social y Grupo Roche Syntex de México. Cd. Mx., México. P. 40.
- Aguilar-Santamaría, L., G. Ramírez, P. Nicasio, C. Alegría-Reyes and A. Herrera-Arellano. 2009. Antidiabetic activities of *Tecoma stans* (L.) Juss. ex Kunth. *Journal of Ethnopharmacology* 124(2): 284-288. DOI: <https://doi.org/10.1016/j.jep.2009.04.033>
- Alarcón-Aguilar, F. J., F. Calzada-Bermejo, E. Hernández-Galicia, C. Ruiz-Angeles and R. Román-Ramos. 2005. Acute and chronic hypoglycemic effect of *Ibervillea sonora* extracts-II. *Journal of Ethnopharmacology* 97(3): 447-452. DOI: <https://doi.org/10.1016/j.jep.2004.11.035>
- Alarcón-Aguilar, F. J., R. Román-Ramos, J. L. Flores-Saenz and F. Aguirre-García. 2002. Investigation on the hypoglycaemic effects of extracts of four Mexican medicinal plants in normal and alloxan-diabetic mice. *Phytotherapy Research* 16(4): 383-386. DOI: <https://doi.org/10.1002/ptr.914>
- Alexander-Lindo, R. L., E. Y. Morrison and M. G. Nair. 2004. Hypoglycaemic effect of stigmast-4-en-3-one and its corresponding alcohol from the bark of *Anacardium occidentale* (cashew). *Phytotherapy Research* 18(5): 403-407. DOI: <https://doi.org/10.1002/ptr.1459>
- Alonso-Castro, A. J., A. C. Miranda-Torres, M. M. González-Chávez and L. A. Salazar-Olivo. 2008. *Cecropia obtusifolia* Bertol. and its active compound, chlorogenic acid, stimulate 2-NBDglucose uptake in both insulin-sensitive and insulin-resistant 3T3 adipocytes. *Journal of Ethnopharmacology* 120(3): 458-464. DOI: <https://doi.org/10.1016/j.jep.2008.09.019>
- Alonso-Castro, A. J., F. Domínguez, J. J. Maldonado-Miranda, L. J. Castillo-Pérez, C. Carranza-Álvarez, E. Solano, M. A. Isiordia-Espinoza, M. C. Juárez-Vázquez, J. R. Zapata-Morales, M. A. Argueta-Fuertes, A. J. Ruiz-Padilla, C. R. Solorio-Alvarado, J. E. Rangel-Velázquez, R. Ortiz-Andrade, I. González-Sánchez, G. Cruz-Jiménez and L. M. Orozco-Castellanos. 2016. Use of medicinal plants by health professionals in Mexico. *Journal of Ethnopharmacology* 198: 81-86. DOI: <https://dx.doi.org/10.1016/j.jep.2016.12.038>
- Andrade-Cetto, A. 1999. Estudio Etnofarmacológico de *Equisetum myriochaetum* Schlechtendal & Chaml. y *Cecropia obtusifolia* Bertol. Tesis de doctorado. Facultad de Ciencias, Universidad Nacional Autónoma de México (UNAM). Cd. Mx., México. 98 pp.
- Andrade-Cetto, A. and H. Wiedenfeld. 2001. Hypoglycemic effect of *Cecropia obtusifolia* on streptozotocin diabetic rats. *Journal of Ethnopharmacology* 78(2-3): 145-149. DOI: [https://doi.org/10.1016/S0378-8741\(01\)00335-X](https://doi.org/10.1016/S0378-8741(01)00335-X)
- Andrade-Cetto, A. and M. Heinrich. 2005. Mexican plants with hypoglycaemic effect used in the treatment of diabetes. *Journal of Ethnopharmacology* 99(3): 325-348. DOI: <https://doi.org/10.1016/j.jep.2005.04.019>
- Andrade-Cetto, A. and R. Cárdenas-Vázquez. 2010. Gluconeogenesis inhibition and phytochemical composition of two *Cecropia* species. *Journal of Ethnopharmacology* 130(1): 93-97. DOI: <https://doi.org/10.1016/j.jep.2010.04.016>
- Andrade-Cetto, A., J. Becerra-Jiménez and R. Cárdenas-Vázquez. 2008. Alfa-glucosidase-inhibiting activity of some Mexican plants used in the treatment of type 2 diabetes. *Journal of Ethnopharmacology* 116(1): 27-32. DOI: <https://doi.org/10.1016/j.jep.2007.10.031>
- Argueta, A. L., L. Cano, L. Asselein and M. E. Rodarte. 1994. Atlas de las plantas de la medicina tradicional mexicana. Instituto Nacional Indigenista (INI) II. Cd. Mx., México. Pp. 706-707.
- Barragán, S. A. 2006. La práctica de la autoatención por fitoterapia en un grupo de familias mexicanas. *Archivos en Medicina Familiar* 8(3): 155-162.
- Berg, C. C., P. F. Rosselli and D. W. Davidson. 2005. *Cecropia*. *Flora Neotropica* 94: 1-230.
- Buenz, E. J., R. Verpoorte and B. A. Bauer. 2017. The ethnopharmacologic contribution to bioprospecting natural products. *Annual Review of Pharmacology and Toxicology* 58(1): 509-530. DOI: <https://doi.org/10.1146/annurev-pharmtox-010617-052703>
- Castillo-España, P., A. Cisneros-Estrada, L. M. Garduño-Ramírez, O. Hernández-Abreu, R. Ramírez and S. Estrada-Soto. 2009. Preliminary ethnopharmacological survey of plants used in Mexico for the treatment of hypertension. *Pharmacognosy Reviews* 3(5): 41-65.
- Choi, R. J., T. M. Ngoc, K. Bae, H. J. Cho, D. D. Kim, J. Chun, S. Khan and Y. S. Kim. 2013. Anti-inflammatory properties of anthraquinones and their relationship with the regulation of P-glycoprotein function and expression. *European Journal of Pharmaceutical Sciences* 48(1-2): 272-281. DOI: <https://doi.org/10.1016/j.ejps.2012.10.027>

- CONABIO. 2017. Ficha *Cecropia obtusifolia* Bertol. Comisión Nacional para el Conocimiento y Uso de la Biodiversidad. México, D.F., México. [http://www.conabio.gob.mx/conocimiento/info\\_especies/arboles/doctos/49-morac3m.pdf](http://www.conabio.gob.mx/conocimiento/info_especies/arboles/doctos/49-morac3m.pdf) (consulted October, 2017).
- Fonseca, R. R., A. Albrechtsen, G. E. Themudo, J. Ramos-Madrigal, J. A. Sibbesen, L. Maretty, M. L. Zepeda-Mendoza, P. F. Campos, R. Heller and R. J. Pereira. 2016. Next-generation biology: Sequencing and data analysis approaches for non-model organisms. *Marine Genomics* 30: 3-13. DOI: <https://doi.org/10.1016/j.margen.2016.04.012>
- Foster, B. C., J. T. Arnason and C. J. Briggs. 2005. Natural health products and drug disposition. *Annual Review of Pharmacology and Toxicology* 45(1): 203-226. DOI: <https://doi.org/10.1146/annurev.pharmtox.45.120403.095950>
- Gabay, O., C. Sanchez, C. Salvat, F. Chevy, M. Breton, G. Nourissat, C. Wolf, C. Jacques C. and F. Berenbaum. 2010. Stigmasterol: a phytosterol with potential anti-osteoarthritic properties. *Osteoarthritis and Cartilage* 18(1): 106-116. DOI: <https://doi.org/10.1016/j.joca.2009.08.019>
- Garber, M., M. G. Grabherr, M. Guttman and C. Trapnell. 2011. Computational methods for transcriptome annotation and quantification using RNA-seq. *Nature methods* 8: 469-477. DOI: <https://doi.org/10.1038/nmeth.1613>
- Ghulam, M., A. Rawaba, A. Asia, S. Sumaira and J. Amer. 2017. Bioactive compounds from medicinal plants and their importance in drug discovery in Pakistan. *Matrix Science Pharma* 1(1): 17-26. DOI: <https://doi.org/10.26480/msp.01.2017.17.26>
- Giovannini, P., M. J. R. Howes and S. E. Edwards. 2016. Medicinal plants used in the traditional management of diabetes and its sequelae in Central America: A review. *Journal of Ethnopharmacology* 184: 58-71. DOI: <https://doi.org/10.1016/j.jep.2016.02.034>
- Guerrero, E. I., J. A. Morrán-Pinzón, L. Gabriel, D. Olmedo, J. L. López-Pérez, A. San Feliciano and M. P. Gupta. 2010. Vasoactive effects of different fractions from two Panamanian plants used in Amerindian traditional medicine. *Journal of Ethnopharmacology* 131(2): 497-501. DOI: <https://doi.org/10.1016/j.jep.2010.06.036>
- Harvey, A. L., R. Edrada-Ebel and J. R. Quinn. 2015. The re-emergence of natural products for drug discovery in the genomics era. *Nature Reviews Drug Discovery* 14(2): 111-129. DOI: <https://doi.org/10.1038/nrd4510>
- Hemmerle, H., H. J. Burguer, P. Below, G. Schubert, R. Rippel, P. W. Schindler, E. Paulus and A. W. Herling. 1997. Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphate translocase. *Journal Medicinal Chemistry* 40(2): 137-143. DOI: <https://doi.org/10.1021/jm9607360>
- Hernández-Galicia, E., F. Calzada, R. Román-Ramos and F. J. Alarcón-Aguilar. 2007. Monoglycerides and fatty acids from *Ibervillea sonora* root: Isolation and hypoglycemic activity. *Planta Medica* 73(3): 1-5. DOI: <https://doi.org/10.1055/s-2007-967117>
- Herrera-Arellano, A., L. Aguilar-Santamaría, B. García-Hernández, P. Nicasio-Torres and J. Tortoriello. 2004. Clinical trial of *Cecropia obtusifolia* and *Marrubium vulgare* leaf extracts on blood and serum lipids in type 2 diabetics. *Phytomedicine* 11(7-8): 561-566. DOI: <https://doi.org/10.1016/j.phymed.2004.01.006>
- Jamaluddin, F., S. Mohamed and M. N. Lajis. 1995. Hypoglycaemic effect of stigmasterol-4-en-3-one, from *Parkia speciosa* empty pods. *Food Chemistry* 54(1): 9-13. DOI: [https://doi.org/10.1016/0308-8146\(95\)92656-5](https://doi.org/10.1016/0308-8146(95)92656-5)
- Kshirsagar, A. D., P. V. Panchal, U. N. Harle, R. K. Nanda and H. M. Shaikh. 2014. Anti-inflammatory and antiarthritic activity of Anthraquinone derivatives in rodents. *International Journal of Inflammation* 2014: 1-12. DOI: <https://doi.org/10.1155/2014/690596>
- Leite, A. C. R., T. G. Araújo, B. M. Carvalho, N. H. Silva, V. L. M. Lima and M. B. S. Maia. 2007. *Parkinsonia aculeata* aqueous extract fraction: Biochemical studies in alloxan-induced diabetic rats. *Journal of Ethnopharmacology* 111(3): 547-552. DOI: <https://doi.org/10.1016/j.jep.2006.12.032>
- Liu, R., X. Li and K. S. Lam. 2017. Combinatorial chemistry in drug discovery. *Current Opinion in Chemical Biology* 2017 38: 117-126. DOI: <https://doi.org/10.1016/j.cbpa.2017.03.017>
- Loizou, S., I. Lekakis, G. P. Chrousos and P. Moutsatsou. 2010.  $\beta$ -Sitosterol exhibits anti-inflammatory activity in human aortic endothelial cells. *Molecular Nutrition & Food Research* 54(4): 551-558. DOI: <https://doi.org/10.1002/mnfr.200900012>
- Martínez-Francés, V., D. Rivera, M. Heinrich, C. Obón and S. Ríos. 2015. An ethnopharmacological and historical analysis of

- "Dictamnus", a European traditional herbal medicine. *Journal of ethnopharmacology* 175: 390-406. DOI: <https://doi.org/10.1016/j.jep.2015.09.011>
- Martínez-Toledo, V., M. Ordáz-Tellez, A. N. Castañeda-Sortibrán, A. Andrade-Cetto and R. Rodríguez-Arnaiz. 2008. Genotoxicity testing of *Cecropia obtusifolia* extracts in two in vivo assays: the wing somatic mutation and recombination test of *Drosophila* and the human cytokinesis-block micronucleus test. *Journal of Ethnopharmacology* 116(1): 58-63. DOI: <https://doi.org/10.1016/j.jep.2007.10.041>
- Mellado, V. and M. Lozoya. 1985. Effect of the aqueous extract of *Cecropia obtusifolia* on the blood sugar of normal and pancreatectomized dogs. *International Journal of Crude Drug Research* 22(1): 11-16. DOI: <https://doi.org/10.3109/13880208409070645>
- Metzker, M. L. 2010. Sequencing technologies-the next generation. *Nature Reviews Genetics* 11: 31-46. DOI: <https://doi.org/10.1038/nrg2626>
- Mochida, K. and K. Shinozaki. 2017. Advances in omics and bioinformatics tools for systems analyses of plant functions. *Plant Cell Physiology* 52: 2017-2038. DOI: <https://doi.org/10.1093/pcp/pcr153>
- Morozova, O., M. Hirst and M. A. Marra. 2009. Applications of new sequencing technologies for transcriptome analysis. *Annual Review of Genomics and Human Genetics* 10: 135-51. DOI: <https://doi.org/10.1146/annurev-genom-082908-145957>
- Nicasio, P., L. Aguilar-Santamaría, E. Aranda, S. Ortiz and M. González. 2005. Hypoglycemic effect and chlorogenic acid content in two *Cecropia* species. *Phytotherapy Research* 19(8): 661-664. DOI: <https://doi.org/10.1002/ptr.1722>
- Ocegueda, S., E. Moreno and P. Koleff. 2005. Plantas utilizadas en la medicina tradicional y su identificación científica. *Biodiversitas* 62: 12-15.
- Ozsolak, F. and P. M. Milos. 2011. RNA sequencing: advances, challenges and opportunities. *Nature Review Genetic* 12: 87-98. DOI: <https://doi.org/10.1038/nrg2934>
- Pan, P. H., S. Y. Lin, Y. C. Ou, W. Y. Chen, Y. H. Chuang, Y. J. Yen, S. L. Liao, S. L. Raung and C. J. Chen. 2010. Stearic acid attenuates cholestasis-induced liver injury. *Biochemical and Biophysical Research Communications* 391(3): 1537-1542. DOI: <https://doi.org/10.1016/j.bbrc.2009.12.119>
- Park, J. G., S. C. Kim, Y. H. Kim, W. S. Yang, Y. Kim, S. Hong, K. H. Kim, B. C. Yoo, S. H. Kim, J. H. Kim and J. Y. Choo. 2016. Anti-inflammatory and antinociceptive activities of anthraquinone-2-carboxylic acid. *Mediators of Inflammation* 1903849: 1-12. DOI: <https://doi.org/10.1155/2016/1903849>
- Pérez, R. M., A. Ocegueda, J. L. Muñoz, J. G. Avila and W. W. Morrow. 1984. A study of the hypoglucemic effect of some Mexican plants. *Journal of Ethnopharmacology* 12(3): 253-262. DOI: [https://doi.org/10.1016/0378-8741\(84\)90054-0](https://doi.org/10.1016/0378-8741(84)90054-0)
- Pérez-Guerrero, C., M. D. Herrera, R. Ortiz, M. Álvarez and M. A. Fernández. 2001. A pharmacological study of *Cecropia obtusifolia* Bertol. aqueous extract. *Journal of Ethnopharmacology* 76(3): 279-284. DOI: [https://doi.org/10.1016/S0378-8741\(01\)00253-7](https://doi.org/10.1016/S0378-8741(01)00253-7)
- Peréz-Gutiérrez, R. M., C. Pérez-González, M. A. Zavala-Sánchez and S. Pérez-Gutiérrez. 1998. Actividad hipoglucemiante de *Bouvardia terniflora*, *Brickellia veronicaefolia* y *Parmen-tiera edulis*. *Salud Pública de México* 40(4): 354-358. DOI: <https://doi.org/10.1590/s0036-36341998000400008>
- Revilla-Monsalve, M. C., A. Andrade-Cetto, M. A. Palomino-Garibay, H. Wiedenfeld and S. Islas-Andrade. 2007. Hypoglycemic effect of *Cecropia obtusifolia* Bertol. aqueous extract on type 2 diabetic patients. *Journal of Ethnopharmacology* 111(3): 636-640. DOI: <https://doi.org/10.1016/j.jep.2007.01.014>
- Rivera-Mondragón, A., O. O. Ortiz, S. Bijttebier, A. Vlietinck, S. Apers, L. Pieters and C. Caballero-George. 2017. Selection of chemical markers for the quality control of medicinal plants of the genus *Cecropia*. *Pharmaceutical Biology* 55(1): 1500-1512. DOI: <https://doi.org/10.1080/13880209.2017.1307421>
- Román-Ramos, R., J. L. Flores-Sáenz, G. Partida-Hernández, A. Lara-Lemus and F. Alarcón-Aguilar. 1991. Experimental study of the hypoglycemic effect of some antidiabetic plants. *Archivos de Investigación Médica* 22(1): 87-93.
- Romero-Cerecero, O., H. Reyes-Morales, L. Aguilar-Santamaría, M. Huerta-Reyes and J. Tortoriello-García. 2009. Use of medicinal plants among patients with diabetes mellitus Type 2 in Morelos, México. *Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas* 8(5): 380-388.
- Ross, S. A., E. A. Gulve and M. Wang. 2004. Chemistry and Biochemistry of Type 2 Diabetes. *Chemical Review* 104: 1255-1282. DOI: <https://doi.org/10.1021/cr0204653>
- Saito, K. and F. Matsuda. 2010. Metabolomics for functional genomics, systems biology, and biotechnology. *Annual Reviews*



- Plant Biology 61: 463-489. DOI: <https://doi.org/10.1146/annurev.arplant.043008.092035>
- Salas, I., J. R. Brenes and O. M. Morales. 1987. Antihypertensive effect of *Cecropia obtusifolia* (Moraceae) leaf extract on rats. Revista de Biología Tropical 35(1): 127-130.
- Sezik, E., M. Aslan, E. Yesilada and S. Ito. 2005. Hypoglycemic activity of *Gentiana olivieri* and isolation of the active constituent through bioassay-directed fractionation techniques. Life Science 76(11): 1223-1238. DOI: <https://doi.org/10.1016/j.lfs.2004.07.024>
- Soda, N., S. Wallace and R. Karan. 2015. Omics study for abiotic stress responses in plants. Advances in Plants & Agriculture Research. 2: 00037. DOI: <https://doi.org/10.15406/apar.2015.02.00037>
- Sukuru, S. C. K., J. L. Jenkins, R. E. J. Beckwith, J. Scheiber, A. Bender, D. Mikhailov, J. W. Davies and M. Glick. 2009. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity. Journal of Biomolecular Screening 14(6): 690-699. DOI: <https://doi.org/10.1177/1087057109335678>
- Tewtrakul, S., P. Tansakul, C. Daengrot, C. Ponglimanont and C. Karalai. 2010. Anti-inflammatory principles from *Heritiera littoralis* bark. Phytomedicine 17(11): 851-855. DOI: <https://doi.org/10.1016/j.phymed.2010.02.011>
- Trejo, G. M. 1983. Estudio fitoquímico de Guarumbo (*Cecropia obtusifolia*) como agente hipoglucemiante. Tesis de licenciatura. Instituto Politécnico Nacional (IPN), Escuela Nacional de Ciencias Biológicas (ENCB). Cd. Mx., México. 55 pp.
- TROPICOS. 2017. Tropicos.org. Missouri Botanical Garden. <http://www.tropicos.org> (consulted September, 2017).
- Villaseñor, J. L. 2016. Checklist of the native vascular plants of Mexico. Revista Mexicana de Biodiversidad 87: 559-902. DOI: <http://dx.doi.org/10.1016/j.rmb.2016.06.017>
- Wang, Z., M. Gerstein and M. Snyder. 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nature Review Genetics 10: 57-63. DOI: <https://doi.org/doi:10.1038/nrg2484>
- Yan, Y., Y. Hao, S. Hu, X. Chen and X. Bai. 2013. Hollow fibre cell fishing with high performance liquid chromatography for screening bioactive anthraquinones from traditional Chinese medicines. Journal of Chromatography A1322: 8-17. DOI: <https://doi.org/10.1016/j.chroma.2013.10.084>